Correlation between mRNA levels and functional role of 1-adrenoceptor subtypes in arteries: evidence of 1L as a functional isoform of the 1A-adrenoceptor by Martí, Daniel et al.
Correlation between mRNA levels and functional role of
1-adrenoceptor subtypes in arteries: evidence of 1L as a
functional isoform of the 1A-adrenoceptor
Daniel Martı´,2,3,* Raquel Miquel,1,* Khalid Ziani,1 Regina Gisbert,1 M. Dolores Ivorra,1
Elsa Anselmi,1 Lucrecia Moreno,3 Victoria Villagrasa,3 Domingo Barettino,2 and Pilar D’Ocon1,4
1Departamento de Farmacologı´a, Facultad de Farmacia, Universitat de Vale`ncia; 2Instituto de Biomedicina
de Valencia, Consejo Superior de Investigaciones Cientı´ficas, Valencia; 3Facultad de Ciencias Experimentales
y de la Salud, Universidad Cardenal Herrera, Valencia; and 4Unidad Mixta, Centro Nacional de
Investigaciones Cardiovasculares—Universitat de Vale`ncia Estudi General, Valencia, Spain
Submitted 23 March 2005; accepted in final form 26 May 2005
Daniel Martı´, Raquel Miquel, Khalid Ziani, Regina Gisbert, M.
Dolores Ivorra, Elsa Anselmi, Lucrecia Moreno, Victoria Villagrasa,
Domingo Barettino, and Pilar D’Ocon. Correlation between mRNA
levels and functional role of 1-adrenoceptor subtypes in arteries: evi-
dence of 1L as a functional isoform of the 1A-adrenoceptor. Am J
Physiol Heart Circ Physiol 289: H1923–H1932, 2005. First published
June 10, 2005; doi:10.1152/ajpheart.00288.2005.—The mRNA levels for
the three 1-adrenoceptor subtypes, 1A, 1B, and 1D, were quantified
by real-time RT-PCR in arteries from Wistar rats. The 1D-adrenoceptor
was prominent in both aorta (79.0%) and mesenteric artery (68.7%), 1A
predominated in tail (61.7%) and small mesenteric artery (73.3%), and
both 1A- and 1D-subtypes were expressed at similar levels in iliac
artery. The mRNA levels of the 1B-subtype were a minority in all
vessels (1.7–11.1%). Concentration-response curves of contraction in
response to phenylephrine or relaxation in response to 1-adrenoceptor
antagonists on maximal sustained contraction induced by phenylephrine
were constructed from control vessels and vessels pretreated with 100
mol/l chloroethylclonidine (CEC) for 30 min. The significant decrease
in the phenylephrine potency observed after CEC treatment together with
the inhibitory potency displayed by 8-{2-[4-(2-methoxyphenyl)-1-pipera-
zinyl]-8-azaspiro (4,5) decane-7-dionedihydrochloride} (BMY-7378, an
1D-adrenoceptor antagonist) confirm the relevant role of 1D-adreno-
ceptors in aorta and iliac and proximal mesenteric arteries. The potency
of 5-methylurapidil (an 1A-adrenoceptor antagonist) and the changes in
the potency of both BMY-7378 and 5-methylurapidil after CEC treat-
ment provided evidence of a mixed population of 1A- and 1D-adreno-
ceptors in iliac and distal mesenteric arteries. The low potency of prazosin
(pIC50 9) as well as the high 5-methylurapidil potency in tail and small
mesenteric arteries suggest the main role of 1A/1L-adrenoceptors with
minor participation of the 1D-subtype. The mRNA levels and CEC
treatment corroborated this pattern and confirmed that the 1L-adreno-
ceptor could be a functional isoform of the 1A-subtype.
chloroethylclonidine; prazosin; mesenteric arteries; adrenergic re-
sponse
THE SYMPATHETIC NERVOUS SYSTEM plays an important role in
regulating the contractile tone of vessels, and it has been
clearly shown that 1-adrenoceptors mediate vasoconstriction
in the peripheral blood circulation. Radioligand binding, mo-
lecular cloning studies, and isolated tissue experiments have
identified three 1-adrenoceptor subtypes that are designated
1A, 1B, and 1D (16, 19). These three subtypes display high
subnanomolar affinities for prazosin. Furthermore, functional
studies have provided evidence for the existence of a fourth
1-adrenoceptor, the 1L-adrenoceptor subtype, which displays
a low affinity for prazosin (pKB  9) and some other 1-
adrenoceptor antagonists (2, 9, 11, 33, 43). This 1L-adreno-
ceptor has no molecular correlate and seems to represent a
functional phenotype of the 1A-adrenoceptor (5, 12, 25).
Previous studies have shown that the mRNAs encoding the
three 1-adrenoceptor subtypes are expressed in different ar-
teries (37). In addition, traditional organ bath studies in the
vessels using selective antagonists have suggested that al-
though only one 1-adrenoceptor subtype seems to be mainly
responsible for the adrenergic response, the results are not
consistent with competitive antagonism at a single site, which
in turn suggests a heterogeneous population of functionally
present subtypes (21, 22, 26, 27, 35, 43).
The present report shows that a methodology combining the
quantification of the mRNA levels by real-time RT-PCR with the
pharmacological characterization of the functional subtypes pro-
vides good correlation among the potencies calculated for each
antagonist and the levels of mRNA for each subtype found in the
vessel. Moreover, this methodology provides additional informa-
tion on minority subtypes and confirms that the 1L-adrenoceptor
could be a functional isoform of the 1A-subtype.
MATERIALS AND METHODS
Real-Time Quantitative RT-PCR
All protocols were approved by the University of Valencia Animal
Ethics Committee (Faculty of Pharmacy Section). Aorta as well as tail,
iliac, mesenteric, and small mesenteric arteries (SMAs) were dissected
and rapidly frozen in liquid nitrogen. Pools of tissues from three animals
were made for small-sized vessels to obtain RNA, but aortas were
processed individually. The frozen tissues were ground to powder in a
mortar and were dissolved in TriPure isolation reagent (Roche). Total
RNA was obtained after chloroform extraction and isopropanol precipi-
tation (following manufacturer’s instructions) and was dissolved in di-
ethyl pyrocarbonate (DEPC)-treated water. The integrity of the RNA
samples was checked by electrophoresis in agarose gel, and RNA
concentrations were estimated spectrophotometrically. Rat genomic
DNA to be used as a standard in real-time PCR was obtained from a rat
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liver crude nuclear fraction. Freshly dissected rat liver tissue (0.5 g) was
homogenized using an Ultra-Turrax dispersing instrument (IKA) in 2 ml
of solution that contained 10 mM Tris HCl, pH 7.5, 10 mM NaCl, 3 mM
MgCl2, and 0.5% Nonidet P-40. After low-speed centrifugation (500 g
for 3 min at 4°C), the crude nuclear fraction present in the pellet was
resuspended in a solution of 10 mM Tris HCl, pH 8.0, 1 mM EDTA, and
10% glycerol. DNase-free RNase A (Sigma) was added to a concentra-
tion of 20 g/ml, and after 10 min at room temperature, SDS was added
to a concentration of 1%, proteinase K (Roche) was added to a concen-
tration of 200 g/ml, and digestion proceeded at 55°C for 16 h. After
digestion, DNA was phenol extracted and precipitated with isopropanol.
The DNA pellet was washed with 70% ethanol, briefly air dried, and
resuspended in water. DNA concentration was estimated spectrophoto-
metrically.
Total RNA (1–2 g) and oligo(dT)16 primer (250 ng) in DEPC-
treated water were preheated to 70°C and cooled on ice for cDNA
synthesis. Reactions (25 l) contained 50 mM Tris HCl (pH 8.3), 75
mM KCl, 3 mM MgCl2, 10 mM DTT, 40 U of RNAsin (Promega), 2
mM of each deoxynucleoside triphosphate, and 300 U of Moloney
murine leukemia virus reverse transcriptase, RNase H minus (Pro-
mega). The reactions were incubated at 42°C for 45 min. A quanti-
tative analysis of the levels of the mRNAs encoding the three
1-adrenoceptor subtypes was performed by real-time RT-PCR with a
GeneAmp 5700 sequence-detection system (Applied Biosystems).
Oligonucleotide pairs were designed for 1A- and 1D-adrenoceptors
and for Gapd as an internal control. The sequences of the primer pair
used for the 1B-adrenoceptor were those included in the report by
Scofield et al. (41). The sequences of the oligonucleotide primers used
in this study, their positions on the corresponding mRNA sequences,
and the expected sizes for the PCR products are shown in Table 1. The
three 1-adrenoceptor subtypes were assayed by real-time PCR on
dilutions of the same RT reaction, and Gapd was used as an internal
control to normalize for differences in the efficiency of reverse
transcription among different samples. We analyzed (in duplicate
reactions) a 10-fold dilution of the RT reaction of each vessel used for
each gene tested; four serial dilutions of genomic DNA (ranging from
the equivalent of 33 to 3,333 copies) were performed to obtain the
standard plot. Water and a mock RT reaction made without reverse
transcriptase were assayed as negative controls. Real-time PCR reac-
tions were set in 25 l with SYBR Green I PCR master mix (Applied
Biosystems) including either 5 l of diluted RT reaction or genomic
DNA and 5 pmol of each primer. The PCR reaction took place with
40 cycles and consisted of denaturation at 95°C for 10 s, annealing at
60°C for 15 s, and extension at 72°C for 20 s. After completion, the
specificity of the reaction was checked by analysis of the thermal
denaturation profile of the product. The threshold cycle values (Ct)
obtained for each 1-adrenoceptor subtype in each RT reaction were
interpolated in the standard plots generated with the genomic DNA,
and the values of copy number per microgram of RNA were calcu-
lated using the GeneAmp 5700 sequence-detection system software
(Applied Biosystems). These absolute values were normalized with
the copy number values obtained for Gapd.
Functional Study in an Isolated Organ Bath
Rings of aorta, tail artery, iliac artery, and mesenteric artery (3–5
mm in length) of female Wistar rats (200–220 g body wt) were
denuded of endothelium by gentle rubbing and were suspended in a
10-ml organ bath that contained a physiological solution maintained at
37°C and gassed with 95% O2-5% CO2. An initial 1-g load was
applied to each preparation and was maintained throughout a 75–90-
min equilibration period. Tension was recorded isometrically from
Grass FTO3 force-displacement transducers, and data were recorded
on a computer disk (MacLab).
Mesenteric arterial trees were dissected and cleared of surrounding
adipose tissue. A ring segment (2 mm in length) from the second
branch of the arterial tree was mounted in a myograph (J. P. Trading;
Aarhus, Denmark) with separate 6-ml organ baths that contained a
physiological solution at 37°C and was gassed with 95% O2-5% CO2
as described previously (54). After a 30-min stabilization period, the
internal diameter of each vessel was set to a tension equivalent to 0.9
times the estimated diameter at 100 mmHg effective transmural
pressure (l100  90–180 m) according to the standard procedure of
Mulvany and Halpern (31). Tension was recorded isometrically, and
data were recorded on a disk (MacLab).
The composition of the physiological solution was (in mmol/l) 118
NaCl, 4.75 KCl, 1.8 CaCl2, 1.2 MgCl2, 1.2 KH2PO4, 25 NaHCO3, and
11 glucose.
After the equilibration period, a sustained contractile response to 10
mol/l phenylephrine (Sigma) was elicited in all vessels, and the
absence of a relaxant response to 10 mol/l acetylcholine (Sigma)
addition indicated the absence of a functional endothelium. The
experimental procedures described below were followed after vessels
were washed and values returned to baseline.
Concentration-response curves for contraction in response
to phenylephrine. A single agonist curve was obtained by the cumu-
lative addition of increasing concentrations of phenylephrine (0.1
nmol/l to 100 mol/l) until a sustained maximal contractile response
(Emax) was obtained in each tissue. The concentration needed to
obtain this maximal response was 1 mol/l in aorta, 10 mol/l in iliac,
tail, and mesenteric arteries, and 30 mol/l in SMAs. After rings were
washed and values had returned to baseline, the irreversible effect of
the alkylating antagonist chloroethylclonidine (CEC; Sigma) was also
evaluated. Rings were exposed to CEC (100 mol/l) for 30 min and
then washed for 60 min before a new cumulative addition of phenyl-
ephrine was carried out.
The concentration needed to obtain 50% of the maximal response
(expressed as pEC50) was calculated from a nonlinear regression plot
(GraphPad Software; San Diego, California).
Concentration-response curves for relaxation in response to selec-
tive 1-adrenoceptor antagonists. Concentration-response curves for
relaxation (CRCR) were performed by the addition of cumulative
concentrations of prazosin (0.001 nmol/l to 1 mol/l; Sigma),
5-methylurapidil (0.001 nmol/l to 10 mol/l; RBI), cyclazosin (0.001
nmol/l to 1 mol/l; Sigma), and 8-{2-[4-(2-methoxyphenyl)-1-pipera-
Table 1. Oligonucleotide primers used in the study
Gene
Gene
Symbol Oligonucleotide Sequences Position*
Product Size,
bp
1A-Adrenergic receptor Adra1a S: 5-CGA ATC CAG TGT CTT CGC AG-3 1059–1078 100
AS: 5-ACC ATG TCT CTG TGC TGT CCC-3 1139–1159
1B-Adrenergic receptor Adra1b S: 5-GCT CCT TCT ACA TCC CGC TCG-3† 1018–1038 300
AS: 5-AGG GGA GCC AAC ATA AGA TGA-3 1298–1318
1D-Adrenergic receptor Adra1d S: 5-GAA GGT GAT GGG TTA TGG TG-3 2321–2340 151
AS: 5-GAA GCC ATA GCT GAA GCC T-3 2454–2472
Glyceraldehyde-3-phosphate dehydrogenase Gapd S: 5-GCA CCA CCA ACT GCT TAG CC-3 1298–1317 100
AS: 5-CTG AGT GGC AGT GAT GGC AT-3 1379–1398
Oligonucleotide sequence orientations are indicated as sense (S) and antisense (AS). *Positions depend on corresponding mRNA sequence in RefSeq NCBI
database (38). †Oligonucleotide primer sequences for Adra1b gene are in accordance with Scofield et al. (41).
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zinyl]-8-azaspiro (4,5) decane-7-dionedihydrochloride} (BMY-7378;
0.001 nmol/l to 10 mol/l; RBI) to tissues in which sustained
contractions had been induced by a maximal concentration of phen-
ylephrine. Relaxations were expressed as a percentage of the maxi-
mum increment in tension obtained by the agonist addition.
In some experiments, the activity of antagonists after incubation
with the alkylating agent CEC was evaluated. Rings from tail, iliac,
and mesenteric arteries and SMAs were exposed to CEC (100 mol/l)
for 30 min and then washed for 60 min before a new addition of the
maximal concentration of phenylephrine was carried out. CRCRs in
response to selective 1-adrenoceptor antagonists were obtained by
the addition of cumulative concentrations of each compound on this
sustained maximal contraction elicited by phenylephrine after CEC
treatment.
The concentration [log(mol/l)] needed to produce 50% relaxation
(pIC50) was obtained from a nonlinear regression plot, and the data
were fitted to one- and two-site models. If residual sums of squares
were statistically less for a two-site fit of data than for a one-site fit as
determined by an F-test comparison, then the two-site model was
accepted (GraphPad Software).
RESULTS
Analysis of 1-Adrenoceptor Subtype mRNA Levels by Real-
Time Quantitative RT-PCR
A two-step real-time RT-PCR assay was used to quantify the
mRNA levels of the three 1-adrenoceptor subtypes in the
different vessels assayed. In the first step, first-strand cDNA
was synthesized from total RNA using Moloney murine leu-
kemia virus reverse transcriptase and oligo(dT)16 as primer.
The product of that RT reaction was used in the second step as
a template for real-time PCR. All four transcripts (the three
1-adrenoceptor subtypes and Gapd as a normalization con-
trol) were analyzed on dilutions of the same RT reaction. In
addition, negative control reactions in which a mock RT
reaction was made without reverse transcriptase or in which the
RT reaction was omitted were analyzed in parallel. The am-
plification plot did not reach the threshold value in these
negative-control reactions. Serial dilutions of rat genomic
DNA were amplified in parallel reactions to construct the
corresponding standard plots. The standard plots in which the
logarithm of the calculated copy number was related to the Ct
value showed slopes close to the theoretical value of 3.33 and
correlation coefficients of r  0.99. The Ct values obtained for
each gene were interpolated on the corresponding standard plot
to obtain the absolute copy number per microgram of RNA,
and those crude values were normalized with the values ob-
tained for Gapd. The normalized values obtained for each
1-adrenoceptor subtype in the different vessels are shown in
Table 2. The results indicate that all three 1-subtypes were
expressed in the vessels analyzed, although there were signif-
icant differences in expression levels. The mRNA for 1D-
adrenoceptor predominated in aorta and mesenteric arteries,
whereas 1A-adrenoceptor was prominent in tail and SMAs.
Both receptor subtypes were expressed to similar levels in iliac
artery. Finally, the mRNA for the 1B-adrenoceptor subtype
was a minority in all tissues. The relative fractions of the three
1-adrenoceptor subtypes in each of the vessels analyzed are
displayed in Fig. 1.
Functional Study in an Isolated Organ Bath
Concentration-response curves of contraction in response
to phenylephrine. A cumulative addition of increasing concen-
trations of phenylephrine to each tissue gave a concentration-
response curve of contraction with Emax and pEC50 values as
summarized in Table 3 and displayed in Fig. 2. This curve
could be reproduced with no significant changes after rings
Table 2. Expression levels of three 1-adrenoceptor subtypes in different vessels
Artery
Expression of Adrenoceptor Subtype, copies/g of RNA
Total Expression,
copies/g of RNA1A 1B 1D
Aorta 29,451.3	14,970.8 10,659.5	3,562.3 151,627.7	93,152.4 191,738.5
Tail 206,922.30	50,342.9 37,357.5	12,020.8 91,493.7	8,187.9 335,773.5
Iliac 22,115.1	4,212.0 4,586.5	1,107.9 20,747.2	2,626.7 47,448.8
Mesenteric 19,257.9	7,249.2 7,102.4	3,827.6 57,797.9	5,776.4 84,158.2
Small mesenteric 22,839.5	4,611.8 524.8	124.5 7,790.4	776.6 31,154.7
Values (which are normalized) are means 	 SE for 3–5 determinations performed in duplicate.
Fig. 1. Relative 1-adrenoceptor subtype composition in the different vessels
studied. Relative levels (in percentages) of the mRNAs for each subtype are
shown with regard to the 1-adrenoceptor mRNA total copy number.
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were washed and values returned to baseline (results not
shown). The higher pEC50 value for phenylephrine in the aorta
indicates that the 1D-subtype plays a fundamental role in this
tissue according to the higher potency and affinity of agonists
for this subtype (30). After CEC treatment, only higher con-
centrations of phenylephrine yielded a contractile response in
aorta; significant decreases in Emax and pEC50 were observed
in mesenteric arteries, and slight but insignificant changes in
Emax and a decrease in pEC50 were observed in tail and iliac
arteries (Table 3 and Fig. 2).
Table 3. Parameters of concentration-response curves of contraction in response




Emax, mg pEC50 Emax, mg pEC50
Aorta 941.7	116.3 7.84	0.04 54.8	21.25‡
Tail 1,091.7	215.9 5.95	0.08 1,063.6	211.8 5.65	0.09*
Iliac 595.6	93.7 6.52	0.16 429.01	105.8 5.03	0.11†
Mesenteric 719.1	64.6 6.93	0.10 343.7	59.5† 5.13	0.21†
Small mesenteric 862.0	69.2 5.95	0.08 679.8	95.6* 5.49	0.13†
Values are means 	 SE of 4–9 experiments. CEC, chloroethylclonidine. *P  0.05, †P  0.01, ‡P  0.01 vs. control.
Fig. 2. Effects of chloroethylclonidine (CEC)
pretreatment on the concentration-response
curve of contraction in response to phenyleph-
rine in isolated rings.
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CRCRs in response to selective 1-adrenoceptor antago-
nists. CRCRs in response to prazosin (an 1-adrenoceptor
antagonist that discriminates for the 1L-subtype), 5-methylu-
rapidil (an 1A-selective antagonist), cyclazosin (an 1B-selec-
tive antagonist; Ref. 13), and BMY-7378 (an 1D-selective
antagonist) were obtained by adding cumulative concentrations
of the compounds to tissues in which sustained contractions
had been induced by concentration of phenylephrine that had
elicited maximal responses. The concentrations of phenyleph-
rine needed to obtain a maximal response in each vessel were
as follows: 1 M in aorta, 10 M in iliac and mesenteric
arteries, and 30 M in tail and SMAs (Fig. 2). The potency
(pIC50) of the fitted curves of relaxation obtained for each
antagonist in the different vessels is summarized in Tables 4
(for aorta), 5 (for tail artery), 6 (for iliac artery), 7 (for
mesenteric artery), and 8 (for second branch of the mesenteric
tree; SMA).
Using the present methodology on rat aorta, we compared
the potency of each antagonist (see Table 4) with the pKi
obtained on cloned 1-adrenoceptors (Table 9), and we con-
cluded that the pIC50 showed by prazosin (9) excluded the
participation of the 1L-subtype in this vessel. The high po-
tency of BMY-7378 indicated the major role of the 1D-
subtype, which was confirmed by the lower potency of
5-methylurapidil and cyclazosin. In this vessel, the lack of an
adequate response to phenylephrine after CEC treatment did
not allow us to analyze the selective antagonist activity in
CEC-pretreated aortas.
In tail artery, the pIC50 obtained with prazosin (see Table 5)
was consistently lower than the affinity reported for cloned
1A-, 1B-, and 1D-subtypes (see Table 9), and it was also
lower than the pIC50 obtained for prazosin in aorta or iliac or
mesenteric arteries (see Tables 4, 6, and 7). The prazosin
potency in tail artery correlated well to the values described for
the functionally defined 1L-adrenoceptors (2, 9, 11, 33, 43).
Concentration-response curves for 5-methylurapidil discrimi-
nated for two different sites (pIC50 Site 1 and pIC50 Site 2; see
Table 5), one of which (pIC50 Site 2) disappeared after CEC
pretreatment as Fig. 3 shows. The 5-methylurapidil potency
after CEC treatment was similar to that observed by site 1 in
untreated vessels and correlated to the pA2 of this antagonist
for the 1A/1L-subtype (2). The cyclazosin potency was not
affected by CEC pretreatment at that time, and we concluded
that the participation of the 1B-subtype was not evident. In
accordance with this and the low tissue sensitivity to CEC
treatment, a major role of the 1A/1L-subtype in tail artery and
a minor role of another CEC-sensitive subtype (probably 1D)
were suggested.
High prazosin potency in iliac artery excluded the functional
role of 1L-adrenoceptors (see Table 6). The concentration-
response curve for 5-methylurapidil provided a significant fit
for two different sites, one of which (pIC50 Site 1) correlated
well with the presence of the 1A-subtype in the vessel (see pKi
values in Table 9). A comparison of the pIC50 value for
BMY-7378 with its pKi value, which was obtained in compe-
tition experiments on cloned 1-adrenoceptor subtypes, sug-
gested the partial role of 1D-adrenoceptors together with (an)
other subtype(s). One of the two affinity sites evidenced by
5-methylurapidil in nontreated iliac arteries disappeared after
Table 6. Values of pIC50 for agents tested on maximal
sustained contractile responses induced
by phenylephrine in rat iliac artery
1-Adrenoceptor
Antagonist
Iliac Artery Iliac Artery 
 CEC
Site 1 pIC50 Site 2 pIC50 n pIC50 n
Prazosin 9.11	0.11 6 ND
BMY-7378 7.61	0.14 5 6.59	0.22* 4
Cyclazosin 8.85	0.10 6 8.40	0.13 5
5-Methylurapidil 8.68	0.27 6.76	0.03 4 8.66	0.10 4
Values are means 	 SE. *P  0.01.
Table 7. Values of pIC50 for agents tested on maximal
sustained contractile responses induced by phenylephrine
in rat proximal or distal mesenteric arteries
1-Adrenoceptor
Antagonist
Mesenteric Artery Mesenteric Artery 
 CEC
Site 1 pIC50 Site 2 pIC50 n pIC50 n
Prazosin P: 10.2	0.08* 6 ND
D: 9.62	0.12
BMY-7378 P: 9.81	0.13 P: 7.53	0.11 4 ND
D: 6.97	0.09 8
Cyclazosin P: 10.23	0.10* 6 8.89	0.20 6
D: 9.32	0.10
5-Methylurapidil P: 10.3	0.29 P: 7.46	0.34 4 9.54	0.08 4
D: 9.34	0.39 D: 7.06	0.19 5
Values are means 	 SE; n, no. of experiments. Region of mesenteric artery
is described as a proximal (P) or distal (D) section with regard to aorta.
*Data from Ziani et al. (54).
Table 4. Values of pIC50 for agents tested on maximal
sustained contractile responses induced
by phenylephrine in rat aorta





Values are means 	 SE; n, no. of experiments. BMY-7378, 8-{2-[4-(2-
methoxyphenyl)-1-piperazinyl]-8-azaspiro (4,5) decane-7-dionedihydrochlo-
ride}. Maximal contraction was induced with 1 mol/l phenylephrine.
Table 5. Values of pIC50 for agents tested on maximal
sustained contractile responses induced





Site 1 pIC50 Site 2 pIC50 n pIC50 n
Prazosin 8.80	0.12 7 ND
BMY 7378 6.40	0.10 7 ND
Cyclazosin 8.22	0.11 6 8.34	0.26 5
5-Methylurapidil 8.73	0.10 5.88	0.26 9 7.97	0.10 6
Values are means 	 SE; n, no. of experiments. Site 1 pIC50 represents
values of agents tested on 10 mol/l phenylephrine induced maximal contrac-
tion when curve fitting for one site was statistically significant or for first site
when curve fitting for two different sites was statistically significant (see data
analysis). Site 2 pIC50 represents value obtained for a second site when curve
fitting for two different sites was statistically significant (see data analysis).
Tail 
 CEC, tail artery pretreated with 100 mol/l chloroethylclonidine for 30
min and subsequent washing of CEC. ND, not determined.
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CEC treatment, and the site that remained sensitive to 5-methyl-
urapidil antagonism correlated well with the 1A-adrenoceptor
subtype (see Table 6 and Fig. 3). In addition, the lower potency
shown by BMY-7378 after CEC treatment suggested that the
1D-adrenoceptors were irreversibly alkylated by CEC (see
Table 6 and Fig. 3). The cyclazosin potency did not signifi-
cantly decrease after CEC treatment. Therefore, the functional
role of the 1B-adrenoceptor was not clearly shown by this
antagonist. According to these results, a mixed population of
1A- and 1D-adrenoceptors were functionally active in iliac
artery.
The high prazosin potency in mesenteric artery (see Table 7)
excluded the functional role of 1L-adrenoceptors. CRCRs for
BMY-7378 showed marked differences depending on the por-
tion of the artery used. BMY-7378 discriminates for two sites
in the section close to aorta (proximal section); one of them,
which corresponded to the 1D-subtype, was not evident in the
distal section of the vessel (see Table 7). That the concentra-
tion-response curves for 5-methylurapidil provided the best fit
to the two-site model suggests the participation of the 1A-
subtype and another subtype in the functional response to
phenylephrine. Pretreatment of mesenteric artery with CEC
destroyed this adrenoceptor population, and posterior concen-
tration-response curves for 5-methylurapidil yielded a value of
pIC50 for one site (see Table 7 and Fig. 3) that correlated well
with the pKi obtained on cloned 1A-adrenoceptors (see Table
9). The potency shown by cyclazosin after CEC treatment was
not significantly lower than the value obtained from nontreated
arteries (see Table 7); thus the role of 1B-adrenoceptors was
not confirmed by this antagonist. According to these results, a
mixed population of 1A- and 1D-adrenoceptors were func-
tionally active in this artery, where the role of 1D-adrenocep-
tors was seen to be greater in the portion of mesenteric artery
close to aorta.
The pIC50 value obtained for prazosin in SMA (see Table 8)
correlated well with its affinity for the 1L-subtype (pA2  9).
BMY-7378 inhibited phenylephrine-induced contraction with
a low potency that excluded the major participation of the
1D-subtype in this vessel. The pIC50 value obtained with
5-methylurapidil corroborated that the 1A/1L-subtypes were
mainly responsible for the adrenergic response in this tissue.
No direct evidence for the participation of the 1B-subtype was
obtained when cyclazosin was used as an antagonist.
DISCUSSION
In the present work, we propose a new methodology that not
only simplifies the pharmacological analysis of the population
of 1-adrenoceptor subtypes that are functionally active in a
vessel but also provides additional information about the nature
of the other subtypes involved in the adrenergic response.
Our method includes the quantification of mRNA levels for
each subtype by real-time quantitative RT-PCR and the real-
ization of concentration-response curves of contraction in re-
sponse to cumulative concentrations of phenylephrine before
and after CEC treatment. Changes in the parameters of these
curves (Emax and pEC50) offer valuable information that is
complemented by the CRCRs of selective antagonists on max-
imal phenylephrine-induced contraction before and after CEC
treatment.
The present state of knowledge with respect to CEC-irre-
versible inactivation of 1-adrenoceptor subtypes is that the
1A-subtype is “insensitive,” the 1B-subtype is “sensitive,”
and the 1D-subtype is “partially sensitive” to this alkylating
agent. However, it is now clear that CEC is able to inactivate
all of the 1-adrenoceptors (37), and differences between
subtypes may be due to 1) the alkylation rate, which is lower
in the 1A-subtype (slowly alkylated) than in the 1B- or
1D-subtypes (rapidly alkylated) according to Xiao and Jeffries
(52); and 2) the subcellular localization of subtypes; namely,
CEC preferentially alkylates the accessible cell surface of
1-adrenoceptors (20, 47). In this way, recent studies have
shown major differences in the subcellular distribution of the
1-subtypes in that 1B-adrenoceptors are located at the cell
membrane and 1A-adrenoceptors are also located (but intra-
cellularly so) at the cell membrane, whereas very little surface
expression of the 1D-adrenoceptors was detected, and the
main localization of this subtype is in a perinuclear orientation
(4, 10, 18, 20, 28, 37, 47).
Table 8. Values of pIC50 for agents tested on maximal
sustained contractile responses induced by phenylephrine








pIC50 n pIC50 n
Prazosin 8.48	0.28 6
BMY-7378 6.30	0.14 8
Cyclazosin 9.36	0.20 6 8.92	0.22 6
5-Methylurapidil 7.98	0.11 7 8.15	0.08 7
Values are means 	 SE for agents tested on 30 mol/l phenylephrine-
induced maximal contraction; n, no. of experiments.









9.2,1 8.5,2 8.6,3 8.65,4 9.12/9,5
8.5/8.7,6 8.697
1B




7.7,16.8,2 6.9,3 7.22,4 7/7.5,5
6.6/6.5,6 5.987
1D




8.0,1 7.8,2 7.3,3 7.59,4 7.3/7.92,5
7.2/7.1,6 6.307
Values are from 1Ford et al. (12), 2Kenny et al. (26), 3Michel et al. (29), 4Muramatsu et al. (32), 5Saussy et al. (39), 6Schwinn et al. (40), 7Testa et al. (46),
8Goetz et al. (17), and 9Yang et al. (53).
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If we are to take both considerations into account, we can
understand why 1B-adrenoceptors are the more sensitive sub-
type to CEC alkylation and 1A-adrenoceptors are the more
resistant subtype, and why the 1D-subtype shows a complex
pattern of alkylation that leads to the designation of this
receptor as “partially sensitive” to CEC depending on the
percentage present in the membrane and, therefore, on its
accessibility to the alkylating agent.
According to the aforementioned information, we can use
CEC in functional studies to analyze the 1-adrenoceptor
subtype that is responsible for the contractile response of a
given vessel. However, great care must be taken with the
experimental conditions with regard to the concentration of
CEC employed and the time the alkylating procedure lasts.
These two parameters determine whether one, two, or three
subtypes are affected by the alkylating agent to a greater or
lesser extent.
The most commonly used CEC concentration is 100 mol/l,
and a general agreement on this point exists. Lower concen-
trations give more confusing results. The alkylation time varies
between 20, 30, and 45 min, but a 30-min time is mainly used
since data in the literature demonstrate that most of the 1B-
and 1D-adrenoceptors are destroyed with an alkylation time
30 min, but most of the 1A-adrenoceptors remain function-
ally active in isolated organ-bath studies (23, 27, 34). CEC at
a concentration of 100 mol/l for 30 min was used in this study
in accordance with these previous data to mainly inactivate the
1B- and 1D-adrenoceptors and to avoid significantly affect-
ing the 1A-subtype.
The major role of 1D-adrenoceptors in rat aorta previously
reported (14, 15, 22, 26) is supported in this study by 1) the
higher levels of mRNA found for this subtype; 2) the highest
pEC50 for phenylephrine observed in this tissue, which con-
firms the higher affinity for this agonist as shown by the
1D-subtype (30); and 3) the fact that the response to phenyl-
ephrine dramatically decreased after CEC treatment according
to the sensitivity of the 1D-subtype for the alkylating agent.
If the mRNA levels in tail artery and SMAs were consid-
ered, the most expressed subtype was 1A-adrenoceptors. The
lower phenylephrine potency compared with aorta together
with the minor sensitivity of these vessels to CEC treatment
confirms the major presence of other subtypes different from
1D-adrenoceptors, although the minor participation of this
subtype was suggested by the significant decrease in the
phenylephrine potency after CEC treatment. That 5-methylu-
rapidil discriminates for two different sites in the tail artery
(pIC50 values of 1 and 2; see Table 5) confirms the main role
of 1A-adrenoceptors as other authors and ourselves have
proposed (14, 27, 35, 36, 45). Nonetheless, this also suggests a
minor role of another subtype, 1D-adrenoceptors, if the results
obtained with the agonist are considered. These observations in
functional studies correlate well with the levels of mRNA
found for each subtype in this vessel, where the mRNA for
1A-adrenoceptors is the most expressed, although a significant
level of mRNA for the 1D-subtype was also quantified in this
tissue. The participation of the 1D-subtype observed in our
experiments is not clearly shown by the classical Schild anal-
ysis, and using this analysis, it only becomes evident after
reserpine treatment (45).
An interesting observation is that together with the higher
mRNA levels for the 1A-subtype that we observed in tail and
SMAs, the prazosin potency correlates well with its affinity for
Fig. 3. Effects of CEC pretreatment on the
concentration-response curves of relaxation by
the 1-adrenoceptor antagonists in different
vessels. Arterial rings were incubated with 100
mol/l CEC for 30 min, extensively washed
out, maximally contracted by phenylephrine,
and exposed to cumulative concentrations of
each antagonist.
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the 1L-adrenoceptor. We can therefore propose that the 1L-
subtype is mainly responsible for the adrenergic response in
both vessels, which is in accordance with the proposal of Ford
et al. (12) and Daniels et al. (5) regarding the nature of the
1L-adrenoceptor as a functional isoform of the 1A-subtype.
This also confirms the main role of 1A/1L-adrenoceptors in
SMAs as described by other authors (43).
Functional experiments in iliac artery confirm the results
obtained by real-time RT-PCR quantification where similar
mRNA levels for the 1A- and 1D-subtypes were found that
were consistent with previous studies that describe 1A-, 1B-,
and 1D-mRNA in this tissue (35). The potency of each
antagonist before and after CEC treatment also confirms the
participation of 1A- and 1D-adrenoceptors in the functional
response of iliac artery and can be summarized as follows: 1)
one of the two sites discriminated by 5-methylurapidil in
non-CEC-treated tissues disappears after CEC treatment; the
site that remains is the one for which 5-methylurapidil shows
a higher potency, and this potency correlates well with its
affinity for the cloned 1A-subtype; 2) the potency of cyclazo-
sin does not change after CEC treatment; 3) BMY-7378 po-
tency decreases in CEC-treated tissues with respect to non-
treated tissues, and it correlates well with its affinity for the
1A- or 1B-subtypes. This could be interpreted as an irrevers-
ible alkylation by CEC of the 1D-adrenoceptor population
present in the vessel.
Finally, the results obtained in mesenteric artery suggest a
main role for the 1D-subtype according to the mRNA levels,
although its role is not as significant as in aorta. Furthermore,
the 1A-subtype expression is increased with respect to aorta.
In functional studies, BMY-7378 potency was different de-
pending on the portion of the vessel considered, and sensitivity
to CEC treatment was lower than in aorta. In fact, BMY-7378
and 5-methylurapidil discriminate for two different sites (sites
1 and 2; see Table 7) in mesenteric artery, but BMY-7378 only
discriminates for the portion close to aorta, which suggests a
predominant but not exclusive role for 1D-adrenoceptors in
proximal segments. BMY-7378 potency was lower in the distal
portion, which suggests minor 1D-adrenoceptor involvement
in the responses of this portion to adrenergic stimulus. The
above considerations suggest a mixed population of 1A- and
1D-adrenoceptors in mesenteric artery that changes according
to an anatomical pattern related to the proximity to aorta. These
results confirm previous studies reported by other authors who
used the Schild analysis (1, 22, 49, 51). In this vessel, although
differences in mRNA expression for the 1A- and 1D-subtypes
were slight with respect to aorta, the functional role of the
1A-subtype is more evident than in aorta. If we consider that
1A-adrenoceptors are efficiently coupled to second-messenger
production, whereas 1D- adrenoceptors are poorly coupled to
it (14, 40), we can assume that slight increases in 1A-
adrenoceptor expression together with slight decreases in 1D-
adrenoceptor levels could have a repercussion for 1A func-
tionality in mesenteric artery. This would account for the lower
sensitivity of this vessel to CEC treatment and also for the
discrimination of BMY-7378 for two sites in mesenteric artery
and not in aorta.
It is interesting to point out that the potency of the different
antagonists calculated with our experimental procedure corre-
lated well with the potency found by other authors and our-
selves using the Schild plot analysis (we must compare present
results to the pA2 values obtained in previous studies and
summarized in Table 10). There is an advantage in that our
procedure facilitates the pharmacological analysis of a tissue,
since the number of experiments and samples is considerably
reduced (about four times) without a decrease in the accuracy
of results. Another advantage this methodology offers is that
the mathematical analysis of the inhibition curves allows us to
statistically compare the adjustment to one- or two-site models,
which is additional evidence of the minor participation of other
subtypes.
When we applied this methodology, we found that either the
1D- or 1A/1L-subtypes had a clear functional role in all
vessels studied, yet a relevant role for the 1B-subtype was not
found in any vessel, thus confirming previous observations
(37). In the same way, the mRNA levels for this subtype were
significantly lower than the other two in all the vessels. This
observation suggests one role of the 1B-subtype as being a
modulator of the functionality of the other subtypes as we have
previously proposed for native receptors (8) and as other
authors have studied in cells coexpressed with either the 1B-
and 1A-subtypes (44) or the 1B- and 1D-subtypes (18).
The quantification of the mRNA levels corroborates the
main functional role observed by 1D-adrenoceptors in con-
ductance vessels and also by 1A-adrenoceptors in either dis-
tributing or resistance vessels. Considering that 1D-adreno-
ceptors are responsible for the slow appearance and slow
disappearance of adrenergic responses, whereas 1A-adreno-
ceptors provide faster responses (8, 15, 54), the higher expres-
sion of 1D-adrenoceptors in poorly innervated conductance
vessels avoids abrupt changes in vessel caliber and, conse-
quently, in blood flow in response to the adrenergic stimulus.
On the contrary, the higher expression of 1A-adrenoceptors in
the densely innervated distributing vessels and particularly in
the resistance vessels guarantees a faster contractile response to
an adrenergic stimulus that is followed by a faster decrease in




Aorta 9.8,1 9.85,2 9.5,3 9.9,4 9.45 7.8,1 7.6,2 6.8,5 7.8,6 7.3,7 7.64,8 8.69 8.3,5 8.06,7 8.56,8 8.6,9 8.9,10 9.0,11 8.5,12
Tail 8.4,5 8.9,6 9.39 8.0,5 9.06 5.8,5 6.3,6 6.512
Iliac 9.313 8.7113 6.62,13 8.414
Mesenteric 9.96 7.9,4 8.05,7 7.712 8.8,4 6.6,7 8.712
Small mesenteric 8.5,15 8.3–8.816 9.117 6.1616
Values are from 1Kenny et al. (26), 2Testa et al. (46), 3Saussy et al. (39), 4Hussain and Marshall (22), 5Gisbert et al. (15), 6Lachnit et al. (27), 7Dhein et al.
(7), 8Asbun-Bojalil et al. (3), 9Taki et al. (45), 10Goetz et al. (17), 11Deng et al. (6), 12Arevalo-Leo´n et al. (1), 13Shibano et al. (42) in mouse, 14Villalobos-Molina
et al. (50), 15Van der Graaf et al. (48), 16Stam et al. (43), and 17Ipsen et al. (24).
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tone after removal. These observations together with the dif-
ferent sensitivities to agonists exhibited by each subtype (lower
for 1A/1L than for 1D) explain the specific distribution of
each subtype through the arterial tree and allow for a fine
adjustment of both contractile tone and blood flow to the
adrenergic stimulus.
In conclusion, present data show that a combination of
quantified mRNA levels along with functional studies includ-
ing CEC treatment proves to be a useful tool to analyze the
exact role of each 1-adrenoceptor subtype in a given vessel. In
addition, the higher mRNA level for the 1A-subtype that is
found in some vessels together with the functional role of
1L-adrenoceptors in these vessels provides additional evi-
dence regarding the proposal that 1L-adrenoceptors are a
functional isoform of the 1A-subtype.
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